Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 3, 2019

View Archived Issues

In seizures ER stress is best bad option

BlueWillow Biologics receives support to develop peanut allergy vaccine

Sabin Vaccine Institute granted BARDA funding to develop Ebola Sudan and Marburg vaccines

Phase I study of CSL-200 gene therapy in adults with severe sickle cell disease

First patient dosed in global phase III pivotal study of zilucoplan for gMG

Promising preclinical data presented for EmtinB glaucoma program

Recruitment ongoing in phase I/II study of IMSA-101 in refractory malignancies

Preliminary data presented for patients with mTNBC enrolled in PIVOT-02 study

Circulating total leptin as a diagnostic and prognostic biomarker in critically ill septic patients

Death receptor 5 as novel biomarker in acute respiratory distress syndrome

CPC-634 shows prolonged higher systemic and intratumoral docetaxel exposure

Vulnerabilities exploited for liver cancer treatment

Shanghai HaiHe Biopharma, Shanghai Institute of Materia Medica patent mutant EZH2 inhibitors

US Department of Health & Human Services and collaborators describe D1 receptor PAMs

IOCB Prague and Univerzita Palackeho v Olomouci disclose nucleoside derivatives

Discovery of novel small-molecule inhibitor of PWWP1 domain of NSD3 for acute myeloid leukemia

Biomica begins preclinical studies with microbial consortia BMC-321 and BMC-322 for IBD

Adynxx receives funding award to develop nonopioid chronic pain product candidate

New GABRA5 inverse agonists discovered at Shanghai SIMR Biotech

Shanghai Allist Pharmaceutical describes new PARP inhibitors

XBiotech initiates phase II study of bermekimab in systemic sclerosis

Phase III THEMIS-PCI results on ticagrelor published

Actinogen reports cognition data on Xanamem in healthy elderly subjects

Phase II data show efficacy of TTP-399 as an adjunctive therapy for type 1 diabetes